Refine
Has Fulltext
- yes (20)
Is part of the Bibliography
- yes (20)
Year of publication
Document Type
- Journal article (20)
Language
- English (20)
Keywords
- multiple myeloma (14)
- CXCR4 (3)
- lenalidomide (3)
- medicine (3)
- molecular imaging (3)
- FDG (2)
- PET (2)
- amplicon sequencing (2)
- amyloidosis (2)
- bone disease (2)
- bortezomib (2)
- deformation (2)
- echocardiography (2)
- ejection fraction (2)
- pomalidomide (2)
- positron emission tomography (2)
- prognosis (2)
- stem-cell transplantation (2)
- theranostics (2)
- 18FDG-PET/CT (1)
- AKT-signaling (1)
- Antibodies (1)
- CXCR4/SDF-1 (1)
- FDG PET/CT (1)
- FDG-PET/CT (1)
- Hepatitis B virus reactivation (1)
- KRAS (1)
- MEK/ERK-signaling (1)
- Multiple myeloma (1)
- Myeloma cells (1)
- Myelomas (1)
- PET/CT (1)
- Positron emission tomography (1)
- SLAMF7 (1)
- \(^{11}\)C-Methionine-PET (1)
- \(^{11}\)C-methionine (1)
- \(^{18}\)F-FDG PET/CT (1)
- abnormalities (1)
- adverse events (1)
- artificial intelligence (1)
- autologous transplantation (1)
- biosynthesis (1)
- bone marrow cells (1)
- bone remineralization (1)
- calcium imaging (1)
- cancer (1)
- cardiac transplantation (1)
- cell staining (1)
- cells (1)
- chemokine receptor (1)
- combination therapy (1)
- computed tomography (1)
- death rates (1)
- deletion 17P (1)
- depression (1)
- diagnostic medicine (1)
- elotuzumab (1)
- esophagogastric junction (1)
- experience (1)
- growth-factor receptor 3 (1)
- high-risk cytogenetics (1)
- imaging techniques (1)
- in vivo imaging (1)
- induction regimen (1)
- intergroupe francophone (1)
- involvement (1)
- kidney (1)
- lenalidomide-refractory patients (1)
- lesions (1)
- malignancies (1)
- management (1)
- microenvironment (1)
- myeloma (1)
- natural language processing (1)
- newly diagnosed (1)
- observational (1)
- ontology (1)
- participation in clinical trials (1)
- plus dexamethasone (1)
- quality of life (1)
- radionuclide therapy (1)
- rare SNP (1)
- real world evidence (1)
- receptor tyrosine kinases (1)
- regression analysis (1)
- renal failure (1)
- safety (1)
- stem cell transplantation (1)
- survival (1)
- therapy (1)
- translocation (1)
- treatment response (1)
- whole-body imaging (1)
Institute
- Medizinische Klinik und Poliklinik II (18)
- Klinik und Poliklinik für Nuklearmedizin (6)
- Pathologisches Institut (5)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (2)
- Institut für diagnostische und interventionelle Radiologie (Institut für Röntgendiagnostik) (2)
- Medizinische Klinik und Poliklinik I (2)
- Deutsches Zentrum für Herzinsuffizienz (DZHI) (1)
- Institut für Humangenetik (1)
- Institut für Informatik (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
Sonstige beteiligte Institutionen
The aim of this study was to investigate the prognostic value of 18F-fluoro-deoxyglucose positron emission tomography–computed tomography (18F-FDG-PET/CT) in 37 patients with a history of multiple myeloma (MM) and suspected or confirmed recurrence after stem cell transplantation (SCT). All patients had been heavily pre-treated. Time to progression (TTP) and overall survival (OS) were correlated to a number of different PET-derived as well as clinical parameters. Impact on patient management was assessed.
Absence of FDG-avid MM foci was a positive prognostic factor for both TTP and OS (p<0.01). Presence of >10 focal lesions correlated with both TTP (p<0.01) and OS (p<0.05). Interestingly, presence of >10 lesions in the appendicular skeleton proved to have the strongest association with disease progression. Intensity of glucose uptake and presence of extramedullary disease were associated with shorter TTP (p=0.037 and p=0.049, respectively). Manifestations in soft tissue structures turned out to be a strong negative predictor for both, TTP and OS (p<0.01, respectively). PET resulted in a change of management in 30% of patients.
Our data underline the prognostic value of 18F-FDG-PET/CT in MM patients also in the setting of post-SCT relapse. PET/CT has a significant impact on patient management.